PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
11062276-3	2000	METHODS: A LMWH, enoxaparin 1 mg/kg BID, was used as bridging anticoagulation therapy in 24 consecutive patients admitted to a university stroke center in whom the treatment plan included transition from acute to chronic anticoagulation.	Enoxaparin	17-27	BH3 interacting domain death agonist	Homo sapiens	36-39	
15249498-3	2004	The recommended dose of enoxaparin of 1 mg/kg BID was used throughout the population except when physicians decided on dose reduction because of a history of a recent bleeding event or because of a high bleeding risk.	Enoxaparin	24-34	BH3 interacting domain death agonist	Homo sapiens	46-49	
22345487-2	2012	Two enoxaparin regimens are approved for thromboprophylaxis, one in the United States (30 mg twice daily [bid]) and another in the rest of the world (40 mg once daily [qd]).	Enoxaparin	4-14	BH3 interacting domain death agonist	Homo sapiens	106-109	
29958743-2	2018	Considering his clinical stability and sPESI 0, enoxaparin 1 mg/kg BID was started for 24 h, and the patient was then considered for early discharge with apixaban 10 mg BID.	Enoxaparin	48-58	BH3 interacting domain death agonist	Homo sapiens	67-70	
28781584-6	2017	Lovenox 90 mg subcutaneous twice daily (1 mg/kg BID) was started together with warfarin to keep INR 2-3.	Enoxaparin	0-7	BH3 interacting domain death agonist	Homo sapiens	48-51	
28228055-14	2017	Weight-based enoxaparin dosing (0.5 mg/kg/dose BID) is an option in trauma patients considered to be at a lower risk of bleeding complications.	Enoxaparin	13-23	BH3 interacting domain death agonist	Homo sapiens	47-50	
26031274-2	2015	Presently, standard dose enoxaparin (30 mg BID) is used as chemical prophylaxis, regardless of weight or physiologic status.	Enoxaparin	25-35	BH3 interacting domain death agonist	Homo sapiens	43-46	
23519234-7	2013	Adjusted indirect comparison showed that bid enoxaparin was significantly more effective in preventing VTE than enoxaparin once daily (relative risk [RR], 0.71; 95% CI, 0.61-0.83; P < .00001).	Enoxaparin	45-55	BH3 interacting domain death agonist	Homo sapiens	41-44	
23519234-8	2013	For major and clinically relevant hemorrhage, adjusted indirect comparison showed that enoxaparin bid was nonsignificantly associated with increased risk of bleeding (RR 1.27; 95% CI, 0.97-1.65; P = .08) above that of enoxaparin once daily.	Enoxaparin	87-97	BH3 interacting domain death agonist	Homo sapiens	98-101	
23519234-8	2013	For major and clinically relevant hemorrhage, adjusted indirect comparison showed that enoxaparin bid was nonsignificantly associated with increased risk of bleeding (RR 1.27; 95% CI, 0.97-1.65; P = .08) above that of enoxaparin once daily.	Enoxaparin	218-228	BH3 interacting domain death agonist	Homo sapiens	98-101	
22824193-5	2012	Patients who underwent therapeutic anticoagulation with a heparin infusion or enoxaparin (1 mg/kg BID) were evaluated for neurologic deterioration or hemorrhage extension by CT scan.	Enoxaparin	78-88	BH3 interacting domain death agonist	Homo sapiens	98-101	
20825842-9	2011	From the 28 patients enrolled, 75% (group 1, n = 21) received at least 0.9 mg/kg per dose BID and 25% (group 2, n = 7) received less than 0.9 mg/kg per dose BID of enoxaparin.	Enoxaparin	164-174	BH3 interacting domain death agonist	Homo sapiens	157-160